BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 29558252)

  • 1. Ibrutinib for the Management of Schnitzler Syndrome: A Novel Therapy for a Rare Condition.
    Jani P; Vissing MB; Ahmed S; Sluzevich JC; Aulakh S; Alegria V; Ailawadhi M; Chanan-Khan A; Ailawadhi S
    J Oncol Pract; 2018 Jun; 14(6):387-388. PubMed ID: 29558252
    [No Abstract]   [Full Text] [Related]  

  • 2. Ibrutinib is an effective treatment for B-cell prolymphocytic leukaemia.
    Gordon MJ; Raess PW; Young K; Spurgeon SEF; Danilov AV
    Br J Haematol; 2017 Nov; 179(3):501-503. PubMed ID: 27391978
    [No Abstract]   [Full Text] [Related]  

  • 3. Ibrutinib is Effective in Refractory Type II Cryoglobulinemia.
    Barot SV; Lee SS; Patel BJ; Valent JN
    Clin Lymphoma Myeloma Leuk; 2019 Dec; 19(12):e629-e632. PubMed ID: 31585822
    [No Abstract]   [Full Text] [Related]  

  • 4. What should standard frontline therapy be in older patients with chronic lymphocytic leukemia? Ibrutinib should be standard frontline therapy.
    Woyach JA
    Clin Adv Hematol Oncol; 2016 May; 14(5):330-3. PubMed ID: 27379693
    [No Abstract]   [Full Text] [Related]  

  • 5. Ibrutinib as salvage therapy in mantle cell lymphoma with central nervous system involvement in a pretreated unfit patient.
    Vitagliano O; Trastulli F; Cacace F; Leone S; Memoli M; Scalia G; Notarangelo M; Mainolfi CG; De Renzo A; Pane F
    Leuk Lymphoma; 2018 Jul; 59(7):1734-1737. PubMed ID: 29019439
    [No Abstract]   [Full Text] [Related]  

  • 6. How I treat CLL patients with ibrutinib.
    Brown JR
    Blood; 2018 Jan; 131(4):379-386. PubMed ID: 29255067
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Final analysis of a phase II study of ibrutinib in Japanese patients with relapsed/refractory mantle cell lymphoma.
    Maruyama D; Nagai H; Fukuhara N; Kitano T; Ishikawa T; Nishikawa T
    J Clin Exp Hematop; 2019; 59(2):98-100. PubMed ID: 31257351
    [No Abstract]   [Full Text] [Related]  

  • 8. Survival adjusting for crossover: phase 3 study of ibrutinib
    Coutre S; Tedeschi A; Robak T; Barr PM; Owen C; Bairey O; Burger J; Zhou C; Styles L; James DF; Kipps TJ
    Haematologica; 2018 Jun; 103(6):e249-e251. PubMed ID: 29170253
    [No Abstract]   [Full Text] [Related]  

  • 9. Outcomes of patients with relapsed/refractory double-expressor B-cell lymphoma treated with ibrutinib monotherapy.
    Landsburg DJ; Hughes ME; Koike A; Bond D; Maddocks KJ; Guo L; Winter AM; Hill BT; Ondrejka SL; Hsi ED; Nasta SD; Svoboda J; Schuster SJ; Bogusz AM
    Blood Adv; 2019 Jan; 3(2):132-135. PubMed ID: 30651281
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ibrutinib in very elderly patients with relapsed/refractory chronic lymphocytic leukemia: A real-world experience of 71 patients treated in France: A study from the French Innovative Leukemia Organization (FILO) group.
    Michallet AS; Campidelli A; Lequeu H; Dilhuydy MS; Tournilhac O; Fornecker LM; Dupuis J; Cymbalista F; De Guibert S; Delmer A; Vilque JP; Ghez D; Leblond V; Subtil F; Feugier P; Ysebaert L
    Am J Hematol; 2017 Jun; 92(6):E105-E107. PubMed ID: 28295510
    [No Abstract]   [Full Text] [Related]  

  • 11. Ibrutinib-associated rash: a single-centre experience of clinicopathological features and management.
    Iberri DJ; Kwong BY; Stevens LA; Coutre SE; Kim J; Sabile JM; Advani RH
    Br J Haematol; 2018 Jan; 180(1):164-166. PubMed ID: 27539794
    [No Abstract]   [Full Text] [Related]  

  • 12. Ibrutinib is a safe and effective therapy for systemic mantle cell lymphoma with central nervous system involvement - a multi-centre case series from the United Kingdom.
    Tucker DL; Naylor G; Kruger A; Hamilton MS; Follows G; Rule SA
    Br J Haematol; 2017 Jul; 178(2):327-329. PubMed ID: 27197509
    [No Abstract]   [Full Text] [Related]  

  • 13. Zanubrutinib: a novel BTK inhibitor in chronic lymphocytic leukemia and non-Hodgkin lymphoma.
    Tam CS
    Clin Adv Hematol Oncol; 2019 Jan; 17(1):32-34. PubMed ID: 30843894
    [No Abstract]   [Full Text] [Related]  

  • 14. A simplified prognostic index for chronic lymphocytic leukemia treated with ibrutinib: Results from a multicenter retrospective cohort study.
    Gordon MJ; Sitlinger A; Salous T; Alqahtani H; Churnetski M; Rivera X; Wisniewski P; Cohen J; Patel K; Shadman M; Choi M; Hill B; Stephens D; Persky D; Brander D; Danilov AV
    Leuk Res; 2020 Feb; 89():106302. PubMed ID: 31982152
    [No Abstract]   [Full Text] [Related]  

  • 15. Pharmacovigilance during ibrutinib therapy for chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) in routine clinical practice.
    Finnes HD; Chaffee KG; Call TG; Ding W; Kenderian SS; Bowen DA; Conte M; McCullough KB; Merten JA; Bartoo GT; Smith MD; Leis J; Chanan-Khan A; Schwager SM; Slager SL; Kay NE; Shanafelt TD; Parikh SA
    Leuk Lymphoma; 2017 Jun; 58(6):1376-1383. PubMed ID: 27820970
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sustained efficacy and detailed clinical follow-up of first-line ibrutinib treatment in older patients with chronic lymphocytic leukemia: extended phase 3 results from RESONATE-2.
    Barr PM; Robak T; Owen C; Tedeschi A; Bairey O; Bartlett NL; Burger JA; Hillmen P; Coutre S; Devereux S; Grosicki S; McCarthy H; Li J; Simpson D; Offner F; Moreno C; Zhou C; Styles L; James D; Kipps TJ; Ghia P
    Haematologica; 2018 Sep; 103(9):1502-1510. PubMed ID: 29880603
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ibrutinib-induced acute liver failure.
    Kahn A; Horsley-Silva JL; Lam-Himlin DM; Reeder CB; Douglas DD; Carey EJ
    Leuk Lymphoma; 2018 Feb; 59(2):512-514. PubMed ID: 28693376
    [No Abstract]   [Full Text] [Related]  

  • 18. What should standard frontline therapy be in older patients with chronic lymphocytic leukemia? Chemoimmunotherapy should be standard frontline therapy.
    Wendtner CM
    Clin Adv Hematol Oncol; 2016 May; 14(5):336-8. PubMed ID: 27379694
    [No Abstract]   [Full Text] [Related]  

  • 19. ibrutinib (IMBRUVICA°) and Waldenström's macroglobulinaemia.
    Prescrire Int; 2016 Oct; 25(175):232. PubMed ID: 30645823
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy of ibrutinib in the treatment of Bing-Neel syndrome.
    Cabannes-Hamy A; Lemal R; Goldwirt L; Poulain S; Amorim S; Pérignon R; Berger J; Brice P; De Kerviler E; Bay JO; Sauvageon H; Beldjord K; Mourah S; Tournilhac O; Thieblemont C
    Am J Hematol; 2016 Mar; 91(3):E17-9. PubMed ID: 26689870
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.